You searched for side effects - Page 64 of 311 - Medivizor
Navigation Menu

Medical conditions and medications my limit the use of desmopressin for nocturia

Medical conditions and medications my limit the use of desmopressin for nocturia

Posted by on Feb 27, 2021 in Nocturia | 0 comments

In a nutshell This study investigated if people with nocturia (waking up at night to urinate) can take desmopressin acetate (Noctiva) medication. Researchers suggested that desmopressin may increase the risk of side effects in older adults with other medical conditions taking many medications. Some background Nocturia means waking up at night to...

Read More

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Posted by on Feb 26, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term survival outcomes of treosulfan (Trecondi)-based versus busulfan (Myleran)-based conditioning treatment in patients with acute myeloid leukemia. This study concluded that treosulfan-based conditioning treatment may have better outcomes for these patients.   Some background...

Read More

Mirabegron improves the symptoms of overactive bladder in patients with Parkinson’s disease

Mirabegron improves the symptoms of overactive bladder in patients with Parkinson’s disease

Posted by on Feb 26, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study investigated the effectiveness and safety of mirabegron (Mirbetriq) for patients with Parkinson’s disease (PD) with overactive bladder (OAB) symptoms. Researchers suggested that mirabegron improved the symptoms of these patients. Some background PD affects brain cells. Over time, these patients experience a variety of...

Read More

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

How do bortezomib, thalidomide,  dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Posted by on Feb 26, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...

Read More

Using long-term CT and PET/CT scans to identify metastatic recurrence in patients with resected melanoma.

Using long-term CT and PET/CT scans to identify metastatic recurrence in patients with resected melanoma.

Posted by on Feb 26, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated how effective regular scanning is in identifying metastatic recurrence in patients with stage III melanoma that was surgically removed. Results showed that scanning every 6 or 12 months was reasonably good at detecting metastatic recurrence. Some background Melanoma is a form of aggressive skin cancer. Treatment...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Evaluating S-1 plus cisplatin with radiotherapy for inoperable stage III non-small cell lung cancer

Evaluating S-1 plus cisplatin with radiotherapy for inoperable stage III non-small cell lung cancer

Posted by on Feb 25, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of chemotherapy with S-1 (Teysuno) plus cisplatin (Platinol) versus docetaxel (Taxotere) plus cisplatin and radiotherapy (RT) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. The authors found that S-1 plus cisplatin (SP) should be considered as a treatment...

Read More